- cafead   Mar 06, 2024 at 12:02: PM
via The FDA on Tuesday approved two of Sandoz’s biosimilars for Amgen’s blockbuster bone-preserving therapy denosumab, though the Novartis spin-off is keeping mum on its target launch date, pricing and other launch details.
article source
article source